Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

120,000 illicit medicines seized in latest MHRA raid

This article was originally published in Scrip

Executive Summary

100,000 Valium (diazepam) tablets and 20,000 other tablets believed to be either unlicensed or counterfeit have been seized by the UK's MHRAin Aylesbury. The medicines included the erectile dysfunction drugs Kamagra tablets, Viagra (Pfizer's sildenafil) and Levitra (Bayer/GlaxoSmithKline/Schering-Plough's vardenafil), as well as the obesity drug Xenical (Roche's orlistat). It is alleged that the drugs were all being sold over the internet. MHRA enforcement officers and police tracked down the medicines in an early morning visit to a residential address in Aylesbury. A man was arrested but has now been released on bail.

You may also be interested in...



Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel